MoonLake Immunotherapeutics (NASDAQ: MLTX) reported positive topline results from its Phase 3 IZAR-1 trial evaluating sonelokimab in biologic-naïve adults with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE